Results 301 to 310 of about 84,688 (355)

Angiotensin II receptor antagonists

The Lancet, 2000
Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of cardiovascular disease with specific pharmacological probes. Oral activity, achieved by shortening the original peptide structures, transformed the probes into therapeutic agents, the angiotensin-converting enzyme (ACE) inhibitors.
M, Burnier, H R, Brunner
openaire   +4 more sources

Angiotensin Receptors and Their Antagonists

New England Journal of Medicine, 1996
Angiotensins are peptide hormones derived from the protein precursor angiotensinogen by the sequential actions of proteolytic enzymes (Figure 1). The classic pathway of angiotensin synthesis includes a reaction catalyzed by angiotensin-converting enzyme (ACE), which occurs not only in plasma but also in the kidneys, brain, adrenal glands, ovaries, and ...
T L, Goodfriend, M E, Elliott, K J, Catt
openaire   +2 more sources

Nonpeptide angiotensin II receptor antagonists

Trends in Pharmacological Sciences, 1991
Substantial progress has been made recently in the development of nonpeptide angiotensin II receptor antagonists, a goal that has long remained an unmet challenge. Pieter Timmermans and colleagues review the pharmacology and the course of events that led to the identification of the lead compound and clinical candidate DuP753. Nonpeptide angiotensin II
P B, Timmermans, P C, Wong, A T, Chiu, W F, Herblin   +3 more
openaire   +2 more sources

Dihydropyrimidine angiotensin II receptor antagonists

Journal of Medicinal Chemistry, 1992
The discovery of the nonpeptide angiotensin II (AII) receptor antagonist losartan, previously called DuP 753, has stimulated considerable interest in the synthesis of novel analogs of this compound. Our efforts in this area have resulted in the discovery of dihydropyrimidines as potent AII receptor antagonists. The chemistry leading to this novel class
K S, Atwal, S Z, Ahmed, J E, Bird, C L, Delaney, K E, Dickinson, F N, Ferrara, A, Hedberg, A V, Miller, S, Moreland, B C, O'Reilly   +9 more
openaire   +2 more sources

Nonpeptide Angiotensin II Receptor Antagonists

American Journal of Hypertension, 1990
Although the most direct way to interfere with the renin-angiotensin system (RAS) is at the level of the angiotensin II (AII) receptor, the currently available AII receptor antagonists are peptides still retaining significant agonistic properties with the obvious drawbacks of limited stability and lack of oral activity.
P B, Timmermans, D J, Carini, A T, Chiu, J V, Duncia, W A, Price, G J, Wells, P C, Wong, R R, Wexler, A L, Johnson   +8 more
openaire   +2 more sources

Angiotensin II receptor antagonists and receptor subtypes

Trends in Endocrinology & Metabolism, 1992
Recently discovered nonpeptide angiotensin II receptor antagonists represent a new class of potential drugs for the treatment of hypertension and congestive heart failure. Further, these antagonists have been successfully used as selective research tools for physiologic studies of angiotensin H and defining angiotensin II receptor subtypes.
P C, Wong, A T, Chiu, J V, Duncia, W F, Herblin, R D, Smith, P B, Timmermans   +5 more
openaire   +2 more sources

Angiotensin II Receptor Antagonists

High Blood Pressure & Cardiovascular Prevention, 2007
Stroke is a devastating disease that heavily affects overall cardiovascular mortality and quality of life in surviving patients, and has a relevant burden on healthcare systems. Recent data derived both from large epidemiological surveys and from the analysis of events occurring in the clinical trials on hypertension, performed over the last 10 years ...
Giuliano Tocci, Francesca Giovannelli, Caterina Facciolo   +2 more
openaire   +1 more source

Angiotensin receptor antagonists

2014
Abstract The renin–angiotensin–aldosterone system (RAAS) is activated in patients with heart failure and contributes to many of the detrimental effects seen in these patients. Antagonists to the angiotensin II type-1 (AT1)-receptor (ARBs) provide a pharmacologically different mechanism of inhibiting the RAAS to ACE inhibitors.
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker   +2 more
openaire   +1 more source

Angiotensin receptor antagonists

Abstract The renin–angiotensin–aldosterone system (RAAS) is activated in patients with heart failure and contributes to many of the detrimental effects seen in these patients. Antagonists to the angiotensin II type-1 (AT1)-receptor (ARBs) provide a pharmacologically different mechanism of inhibiting the RAAS to ACE inhibitors.
Roy S. Gardner, Theresa A. McDonagh, Daniel J. Doherty, Nikki L. Walker   +3 more
openaire   +1 more source